Mazdutide is a dual GLP-1 and glucagon receptor agonist developed for metabolic and weight-management research. It works through pathways involved in appetite regulation, glucose metabolism, and energy balance. Mazdutide received approval in China in 2025 for specified metabolic indications; approval does not extend automatically to other countries or research-vial products.